Cargando…

Helical Tomotherapy for Inoperable Breast Cancer: A New Promising Tool

Background. We investigated the feasibility of helical tomotherapy (HT) for inoperable large breast tumors, after failing to achieve adequate treatment planning with conformal radiation techniques. Material and Methods. Five consecutive patients with locally advanced breast cancer (LABC) were treate...

Descripción completa

Detalles Bibliográficos
Autores principales: Chira, Ciprian, Kirova, Youlia M., Liem, Xavier, Campana, François, Peurien, Dominique, Amessis, Malika, Fournier-Bidoz, Nathalie, Pierga, Jean-Yves, Dendale, Rémi, Bey, Pierre, Fourquet, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775426/
https://www.ncbi.nlm.nih.gov/pubmed/24078909
http://dx.doi.org/10.1155/2013/264306
_version_ 1782477378764668928
author Chira, Ciprian
Kirova, Youlia M.
Liem, Xavier
Campana, François
Peurien, Dominique
Amessis, Malika
Fournier-Bidoz, Nathalie
Pierga, Jean-Yves
Dendale, Rémi
Bey, Pierre
Fourquet, Alain
author_facet Chira, Ciprian
Kirova, Youlia M.
Liem, Xavier
Campana, François
Peurien, Dominique
Amessis, Malika
Fournier-Bidoz, Nathalie
Pierga, Jean-Yves
Dendale, Rémi
Bey, Pierre
Fourquet, Alain
author_sort Chira, Ciprian
collection PubMed
description Background. We investigated the feasibility of helical tomotherapy (HT) for inoperable large breast tumors, after failing to achieve adequate treatment planning with conformal radiation techniques. Material and Methods. Five consecutive patients with locally advanced breast cancer (LABC) were treated by preoperative HT. All patients received up-front chemotherapy before HT. Irradiated volumes included breast and nodal areas (45–50 Gy) in 4 patients. One patient received a simultaneous integrated boost (55 Gy) to gross tumor volume (GTV) without lymph node irradiation. Acute toxicity was assessed with Common Toxicity Criteria for Adverse Events v.4. Patients were evaluated for surgery at the end of treatment. Results. Patients were staged IIB to IIIC (according to the AJCC staging system 2010). HT was associated in 4 patients with concomitant chemotherapy (5-fluorouracil and vinorelbine). Two patients were scored with grade 3 skin toxicity (had not completed HT) and one with grade 3 febrile neutropenia. One patient stopped HT with grade 2 skin toxicity. All patients were able to undergo mastectomy at a median interval of 43 days (31–52) from HT. Pathological partial response was seen in all patients. Conclusions. HT is feasible with acceptable toxicity profiles, potentially increased by chemotherapy. These preliminary results prompt us to consider a phase II study.
format Online
Article
Text
id pubmed-3775426
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-37754262013-09-29 Helical Tomotherapy for Inoperable Breast Cancer: A New Promising Tool Chira, Ciprian Kirova, Youlia M. Liem, Xavier Campana, François Peurien, Dominique Amessis, Malika Fournier-Bidoz, Nathalie Pierga, Jean-Yves Dendale, Rémi Bey, Pierre Fourquet, Alain Biomed Res Int Clinical Study Background. We investigated the feasibility of helical tomotherapy (HT) for inoperable large breast tumors, after failing to achieve adequate treatment planning with conformal radiation techniques. Material and Methods. Five consecutive patients with locally advanced breast cancer (LABC) were treated by preoperative HT. All patients received up-front chemotherapy before HT. Irradiated volumes included breast and nodal areas (45–50 Gy) in 4 patients. One patient received a simultaneous integrated boost (55 Gy) to gross tumor volume (GTV) without lymph node irradiation. Acute toxicity was assessed with Common Toxicity Criteria for Adverse Events v.4. Patients were evaluated for surgery at the end of treatment. Results. Patients were staged IIB to IIIC (according to the AJCC staging system 2010). HT was associated in 4 patients with concomitant chemotherapy (5-fluorouracil and vinorelbine). Two patients were scored with grade 3 skin toxicity (had not completed HT) and one with grade 3 febrile neutropenia. One patient stopped HT with grade 2 skin toxicity. All patients were able to undergo mastectomy at a median interval of 43 days (31–52) from HT. Pathological partial response was seen in all patients. Conclusions. HT is feasible with acceptable toxicity profiles, potentially increased by chemotherapy. These preliminary results prompt us to consider a phase II study. Hindawi Publishing Corporation 2013 2013-09-02 /pmc/articles/PMC3775426/ /pubmed/24078909 http://dx.doi.org/10.1155/2013/264306 Text en Copyright © 2013 Ciprian Chira et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Chira, Ciprian
Kirova, Youlia M.
Liem, Xavier
Campana, François
Peurien, Dominique
Amessis, Malika
Fournier-Bidoz, Nathalie
Pierga, Jean-Yves
Dendale, Rémi
Bey, Pierre
Fourquet, Alain
Helical Tomotherapy for Inoperable Breast Cancer: A New Promising Tool
title Helical Tomotherapy for Inoperable Breast Cancer: A New Promising Tool
title_full Helical Tomotherapy for Inoperable Breast Cancer: A New Promising Tool
title_fullStr Helical Tomotherapy for Inoperable Breast Cancer: A New Promising Tool
title_full_unstemmed Helical Tomotherapy for Inoperable Breast Cancer: A New Promising Tool
title_short Helical Tomotherapy for Inoperable Breast Cancer: A New Promising Tool
title_sort helical tomotherapy for inoperable breast cancer: a new promising tool
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775426/
https://www.ncbi.nlm.nih.gov/pubmed/24078909
http://dx.doi.org/10.1155/2013/264306
work_keys_str_mv AT chiraciprian helicaltomotherapyforinoperablebreastcanceranewpromisingtool
AT kirovayouliam helicaltomotherapyforinoperablebreastcanceranewpromisingtool
AT liemxavier helicaltomotherapyforinoperablebreastcanceranewpromisingtool
AT campanafrancois helicaltomotherapyforinoperablebreastcanceranewpromisingtool
AT peuriendominique helicaltomotherapyforinoperablebreastcanceranewpromisingtool
AT amessismalika helicaltomotherapyforinoperablebreastcanceranewpromisingtool
AT fournierbidoznathalie helicaltomotherapyforinoperablebreastcanceranewpromisingtool
AT piergajeanyves helicaltomotherapyforinoperablebreastcanceranewpromisingtool
AT dendaleremi helicaltomotherapyforinoperablebreastcanceranewpromisingtool
AT beypierre helicaltomotherapyforinoperablebreastcanceranewpromisingtool
AT fourquetalain helicaltomotherapyforinoperablebreastcanceranewpromisingtool